• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

The U.S. spent $30 billion to ditch textbooks for laptops and tablets: The result is the first generation less cognitively capable than their parents

2

Current price of oil as of July 13, 2026

3

Current price of silver as of Monday, July 13, 2026

1

The U.S. spent $30 billion to ditch textbooks for laptops and tablets: The result is the first generation less cognitively capable than their parents

2

Current price of oil as of July 13, 2026

3

Current price of silver as of Monday, July 13, 2026
HealthBloomberg

Opioids Are No Better Than Common Painkillers, Study Finds

By
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Bloomberg
Bloomberg
Down Arrow Button Icon
March 6, 2018, 12:25 PM ET
Add Fortune on Google for similar content.

Doctors and patients have long assumed that opioids are uniquely powerful medicines for chronic pain, despite their risks. But it turns out that this reputation may be a myth.

A government-funded study published Tuesday is among the first long-term studies to compare opioids like oxycodone and morphine to common painkillers such as acetaminophen in patients with chronic back pain and arthritis, researchers said.

After a year of treatment, opioids weren’t any better at improving pain related to daily functioning, such as ability to sleep and work, the study found. The opioids were also slightly inferior at controlling pain intensity, and patients on them reported many more side effects, according to the results published in the Journal of the American Medical Association.

“The fact that opioids did worse is really pretty astounding,” said Roger Chou, an internist at Oregon Health & Science University and a co-author of Centers for Disease Control and Prevention guidelines on opioid use for chronic pain, who was not involved in the recent study. “It calls into question our beliefs about the benefits of opioids.”

The findings run counter to years of medical practice in the U.S., where more so than in other countries, opioids have been prescribed to millions of patients for chronic pain over the years — even though data on their long-term effectiveness was lacking. While doctors are pulling back now, a surge in opioid use and abuse has led to an overdose crisis that kills tens of thousands of Americans each year.

Opoids and Heroin: QuickTake on the U.S. Epidemic of Addiction

The study is also another blow for opioid manufacturers, such as Purdue Pharma LP, that are already facing hundreds of lawsuits filed by U.S. cities and counties over their role in the opioid crisis. More than 300 lawsuits are on hold as the drugmakers engage in settlement talks ordered by the federal judge in Cleveland who is overseeing the litigation.

Chronic Back Pain

In the study, lead author Erin Krebs and her colleagues at the Minneapolis Veterans Affairs Health Care System randomly assigned 240 patients with chronic back pain, or hip or knee arthritis, to be treated either with opioid painkillers like morphine and oxycodone, or nonopioid medicines including standard anti-inflammatory drugs like naproxen, or topical analgesics such as lidocaine.

After a year, about 60 percent of patients in each group experienced significant improvements in their ability to perform daily functions without pain interfering. But pain intensity improved significantly in just 41 percent of patients in the opioid group, compared with 54 percent in the nonopioid group, said Krebs, a primary care doctor at the Minneapolis VA. And patients taking opioids reported experiencing twice as many side effects.

If anything the study should have been biased in favor of the opioids, researchers said, because patients knew what drugs they were getting, and many went into the study believing that opioids were better.

‘Surprising’ Results

The results “will be surprising for a lot of people,” Krebs said. “Opioids have this reputation as powerful painkillers and I don’t think it is well deserved, at least for chronic pain.”

While opioids provide potent relief for acute pain, that doesn’t necessarily translate to a chronic pain situation, where the pain often becomes disassociated from the original injury. Long-term studies haven’t been required for regulatory approval of their sales, and drugmakers have had no incentive do any.

The 2016 CDC chronic pain guidelines co-authored by Chou, the Oregon university internist, found that most controlled studies of opioids lasted less than six weeks. The government agency concluded there was “insufficient evidence” for their long-term benefits, but plenty of evidence for harm.

“This the first randomized trial that demonstrates you do not need opioids for these common chronic pain conditions, that common drugs are as good,” said Gary Franklin, a neurologist and occupational health researcher at the University of Washington who did early studies linking prescription opioid use to fatal overdoses. “That is why this is so important.”

About the Author
By Bloomberg
See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Best Recumbent Bikes (2026): Athlete Approved
HealthDietary Supplements
Best Recumbent Bikes (2026): Athlete Approved
By Christina SnyderJuly 13, 2026
11 hours ago
GOP Sen. Mitch McConnell ends frenzied speculation about his health, revealing a fall led to his hospitalization and he’s now in a rehab center
PoliticsU.S. Senate
GOP Sen. Mitch McConnell ends frenzied speculation about his health, revealing a fall led to his hospitalization and he’s now in a rehab center
By The Associated PressJuly 12, 2026
1 day ago
Manufacturing worker on factory floor
SuccessFlexible work
Fortune 500 Land O’Lakes is letting workers choose what days and times they work—and the flex jobs are getting 25% more applicants than full-time gigs
By Emma BurleighJuly 12, 2026
2 days ago
Other diet fads championed by MAHA are questionable. But some science and thousands of years of human history are behind fermented foods
HealthFood and drink
Other diet fads championed by MAHA are questionable. But some science and thousands of years of human history are behind fermented foods
By Devi Shastri, Mary Conlon and The Associated PressJuly 11, 2026
3 days ago
The 3 Best IgG Food Panel Tests of 2026: Reviewed by Experts
HealthDietary Supplements
The 3 Best IgG Food Panel Tests of 2026: Reviewed by Experts
By Emily PharesJuly 10, 2026
3 days ago
The Best Vitamin D Tests (2026): How to Use at Home and the Lab
HealthDietary Supplements
The Best Vitamin D Tests (2026): How to Use at Home and the Lab
By Christina SnyderJuly 10, 2026
3 days ago

Most Popular

The U.S. spent $30 billion to ditch textbooks for laptops and tablets: The result is the first generation less cognitively capable than their parents
Innovation
The U.S. spent $30 billion to ditch textbooks for laptops and tablets: The result is the first generation less cognitively capable than their parents
By Sasha RogelbergJuly 12, 2026
2 days ago
Current price of oil as of July 13, 2026
Personal Finance
Current price of oil as of July 13, 2026
By Joseph HostetlerJuly 13, 2026
22 hours ago
Current price of silver as of Monday, July 13, 2026
Personal Finance
Current price of silver as of Monday, July 13, 2026
By Joseph HostetlerJuly 13, 2026
22 hours ago
Trump embraces Australian retirement system backed by Larry Fink
Personal Finance
Trump embraces Australian retirement system backed by Larry Fink
By Brianna Sosa and BloombergJuly 12, 2026
1 day ago
How Pete Hegseth's DEI order just put Scouting America's future at stake
North America
How Pete Hegseth's DEI order just put Scouting America's future at stake
By Seth T. Kannarr, Derek H. Alderman and The ConversationJuly 13, 2026
12 hours ago
The U.S. and Iran can't agree on fully reopening the Strait of Hormuz. The solution could be straight out of the Old Testament
Middle East
The U.S. and Iran can't agree on fully reopening the Strait of Hormuz. The solution could be straight out of the Old Testament
By Jason MaJuly 11, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.